Current Collaborations

On July 28, 2016, Galmed entered into a license agreement with Samil Pharma. Co. Ltd. for the commer­cial­ization of Aramchol in Korea. Samil Pharma has an exclusive, royalty‐​bearing license for the commer­cial­ization of Aramchol^™ for the treatment of fatty liver indica­tions including nonal­co­holic steato­hep­atitis (NASH) in Korea. Read More

On July 8, 2015, Galmed entered into a Research, Option and License Agreement with OWL, for the devel­opment of a non‐​invasive, blood‐​based comple­mentary diagnostic tool, which we believe could increase the likelihood of success of our Phase III trials and facil­itate the market adoption of Aramchol. Read More